A llogeneic hematopoietic stem cell transplantation (HSCT) with a myeloablative conditioning regi-men is considered the most potent post-remission antileukemic therapy in adult acute lymphoblastic leukemia (ALL). 1,2 However, an adequate balance should be established between its curative potential, the disadvantages (transplant-related mortality, late complications and reduced quality of life) ...

The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplant...

Wiskott-Aldrich syndrome (WAS) is an X-linked congenital immune-deficiency syndrome, and bone marrow transplantation (BMT) has become a curative modality. However, the transplant with the alternative donor needed more intensive conditioning with increased treatment-related toxicities. Recently, fludarabine-based reduced toxicity myeloablative conditioning regimens have been developed for adult ...

Hematopoietic stem cells (HSCs) inhabit distinct microenvironments within the adult bone marrow (BM), which govern the delicate balance between HSC quiescence, self-renewal, and differentiation. Previous reports have proposed that HSCs localize to the vascular niche, comprised of endothelium and tightly associated perivascular cells. Herein, we examine the capacity of BM endothelial cells (BMEC...

Effect of graft source on unrelated donor haemopoietic stem-cell trans-plantation in adults with acute leukaemia: a retrospective analysis. al. Unrelated transplantation for poor-prognosis adult acute lym-phoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. R, et al. Favorable outcome of unrelated cord blood transplantation for Philadelphia chro...

PURPOSE New strategies that target selected molecular characteristics and result in an effective therapeutic index are needed for metastatic, hormone-refractory prostate cancer. EXPERIMENTAL DESIGN A series of preclinical and clinical studies were designed to increase the therapeutic index of targeted radiation therapy for prostate cancer. (111)In/90Y-monoclonal antibody (mAb), m170, which ta...